background
current
prevent
option
upper
respiratori
infect
uri
optim
conduct
random
doubleblind
placebocontrol
pilot
clinic
trial
evalu
safeti
efficaci
current
market
prevent
uri
method
armsi
patent
novel
formul
prevent
treatment
influenza
compris
broadspectrum
antimicrobi
agent
cetylpyridinium
chlorid
cpc
compon
glycerin
xanthan
gum
form
barrier
host
mucosa
thu
prevent
viral
contact
invas
healthi
adult
year
age
random
armsi
placebo
group
subject
drug
spray
intraor
daili
day
primari
object
establish
whether
armsi
decreas
frequenc
sever
durat
uri
secondari
object
evalu
safeti
toler
rate
viru
detect
accept
adher
effect
uriassoci
absente
medic
visit
effect
prior
influenza
vaccin
studi
outcom
result
individu
complet
studi
placebo
n
armsi
n
six
present
confirm
uri
placebo
armsi
repres
rel
reduct
albeit
statist
signific
influenza
coronaviru
rhinoviru
detect
three
particip
placebo
group
moreov
frequenc
posttreat
exit
visit
reduc
armsi
compar
placebo
group
n
respect
fever
report
placebo
group
armsi
significantli
reduc
frequenc
sever
cough
sore
throat
durat
cough
p
comparison
armsi
safe
well
toler
high
accept
high
adher
medic
use
medic
visit
occur
placebo
group
absente
differ
two
arm
prior
influenza
vaccin
effect
studi
outcom
conclus
random
proofofconcept
clinic
trial
demonstr
armsi
tend
provid
protect
uri
enrol
studi
particip
reduc
sever
durat
cough
sore
throat
clinic
trial
larger
number
studi
particip
warrant
trial
registr
clinicaltrialsgov
retrospect
regist
upper
respiratori
infect
uri
associ
signific
morbid
mortal
particularli
children
elderli
underli
medic
condit
eg
cancer
cardiopulmonari
diseas
diabet
immunosuppress
center
diseas
control
cdc
conduct
review
influenza
case
influenza
season
report
annual
rate
influenzaassoci
death
us
period
rang
death
per
person
moreov
influenza
associ
million
hospit
visit
hospit
annual
infect
associ
noninfluenza
virus
known
caus
million
lost
work
school
day
annual
yearli
econom
burden
due
viral
uri
rang
billion
uri
caus
respiratori
viral
pathogen
includ
influenza
respiratori
syncyti
viru
rsv
human
metapneumoviru
rhinoviru
adenoviru
current
prevent
strategi
influenza
involv
use
vaccin
antivir
medic
although
vaccin
gener
effect
coverag
effect
vari
limit
vaccin
includ
vaccinestrain
mismatch
vaccin
hesit
neuraminidas
inhibitor
nai
eg
oseltamivir
zanamivir
approv
us
prevent
treat
influenza
agent
often
induc
modest
decreas
symptom
durat
peopl
uncompl
ill
nai
also
associ
resist
develop
side
effect
high
cost
limit
effect
therefor
unmet
need
exist
develop
effect
therapeut
approach
prevent
uri
armsi
current
market
develop
firstinclass
novel
dualact
formul
prevent
viral
uri
kill
viru
disrupt
hostderiv
viral
lipid
membran
form
protect
barrier
host
mucosa
recent
group
demonstr
armsi
formul
exhibit
novel
potent
activ
respiratori
virus
vitro
reduc
influenzaassoci
mortal
morbid
influenza
infect
murin
model
current
studi
report
safeti
effect
armsi
prevent
uri
random
doubleblind
placebocontrol
pilot
clinic
trial
armsi
singlestream
oral
spray
target
oral
oropharynx
mucos
surfac
compris
broadspectrum
antimicrobi
agent
cetylpyridinium
chlorid
cpc
disrupt
viral
lipid
envelop
physicochem
interact
compon
glycerin
xanthan
gum
form
barrier
host
mucosa
thu
prevent
viral
contact
invas
current
studi
random
doubleblind
placebocontrol
pilot
clinic
trial
hypothesi
studi
use
activ
product
armsi
spray
intraor
daili
associ
fewer
episod
lower
durat
symptom
sever
acut
uri
acut
uri
defin
combin
three
follow
symptom
fever
nonproduct
cough
sore
throat
rhinorrhea
runni
nose
sinu
congest
stuffi
nose
malais
enrol
target
healthi
men
women
year
old
inclus
health
studi
particip
assess
base
patient
recal
symptom
clinic
assess
inclus
criteria
bmi
kgm
tobacconicotin
use
least
month
nonpregn
breastfeed
inclusionexclus
criteria
studi
design
detail
see
protocol
addit
file
particip
enrol
studi
inform
consent
follow
clinic
trial
protocol
approv
univers
hospit
case
medic
center
institut
review
board
human
investig
cleveland
oh
protocol
number
approv
date
detail
regard
background
inform
elig
particip
elig
criteria
see
full
protocol
addit
file
subject
provid
written
consent
obtain
accord
feder
regul
compens
monetarili
particip
written
document
embodi
element
inform
consent
describ
declar
helsinki
adher
ich
harmon
guidelin
good
clinic
practic
clinic
trial
protocol
went
rigor
review
institut
review
board
adher
compon
necessari
pilot
clinic
studi
natur
moreov
protocol
also
care
vet
clinicaltrialsgov
registr
process
indic
defici
trial
design
addit
current
ongo
clinic
trial
product
studi
particip
random
equal
proport
two
group
activ
product
armsi
administ
intraor
spray
three
time
daili
dose
regimen
select
base
pilot
clinic
studi
evalu
abil
armsi
reduc
oral
microbi
load
b
placebo
purifi
steril
water
contain
flavor
activ
without
neither
activ
antimicrobi
agent
cpc
barrier
form
compon
administ
intraor
spray
three
time
daili
random
list
gener
use
websit
http
wwwrandomizerorg
studi
personnel
except
pharmacist
blind
activ
placebo
agent
selfadminist
daili
particip
day
exit
visit
occur
within
week
posttreat
studi
conduct
respiratori
viru
season
northeastern
ohio
date
rang
patient
recruit
januari
march
complet
june
unblind
juli
primari
object
determin
whether
armsi
decreas
frequenc
acut
uri
assess
whether
armsi
decreas
durat
sever
urirel
symptom
secondari
object
assess
toler
accept
adher
armsi
medic
vs
placebo
compar
whether
acut
uri
receiv
armsi
compar
placebo
associ
differ
absente
work
school
visit
physician
offic
emerg
depart
urgent
care
center
determin
whether
armsi
decreas
detect
respiratori
virus
polymeras
chain
reaction
pcr
evalu
effect
armsi
receiv
influenza
vaccin
endpoint
frequenc
durat
clinic
respiratori
diseas
studi
visit
assist
electron
patient
diari
intraand
extraor
exam
solicit
unsolicit
advers
event
respiratori
viru
multiplex
pcr
selfreport
adher
medic
usag
subjectlevel
characterist
summar
per
studi
group
age
gender
prior
influenza
vaccin
statu
medic
taken
symptom
relief
studi
length
number
studi
survey
complet
use
summar
inform
frequenc
durat
sever
symptom
sever
urirel
symptom
score
scale
none
minor
mild
moder
sever
base
diari
entri
studi
particip
least
three
symptom
use
valid
wisconsin
upper
respiratori
symptom
survey
determin
durat
urisrel
symptom
perform
assess
selfreport
diari
studi
particip
least
three
symptom
identifi
instanc
symptom
present
least
two
consecut
day
frequenc
symptom
occur
least
week
apart
record
distinct
occurr
sinc
multipl
uri
event
occur
per
individu
season
particip
diarybas
uri
event
ask
present
clinic
studi
physician
examin
confirm
clinic
uri
use
research
electron
data
captur
redcap
method
collect
store
dissemin
trialspecif
clinic
data
electron
diari
creat
use
redcap
system
particip
record
symptom
address
studyrel
questionnair
use
electron
diari
data
analysi
perform
address
primari
secondari
object
describ
studi
design
frequenc
uri
assess
base
visit
clinic
studi
particip
least
three
urirel
symptom
sick
visit
confirm
clinic
studi
staff
interview
conduct
studi
nurs
studi
particip
within
week
treatment
complet
analysi
daili
diari
electron
complet
studi
particip
describ
presenc
least
three
symptom
sampl
size
calcul
carri
assum
two
group
would
equal
size
random
assign
would
balanc
assum
averag
two
event
would
occur
control
group
compar
averag
event
treat
group
mean
sd
averag
durat
ill
would
day
day
control
treat
group
respect
mean
sd
respect
take
alpha
sampl
size
per
group
would
allow
detect
differ
primari
outcom
two
group
power
sampl
size
increas
per
group
account
potenti
loss
followup
symptom
uri
investig
separ
endpoint
total
number
day
event
record
number
day
event
per
day
persontim
followup
relat
studi
durat
per
subject
record
group
sinc
prevent
studi
conduct
flu
season
select
day
cover
entir
season
next
logist
regress
model
construct
data
taken
day
level
endpoint
yesno
event
day
furthermor
data
includ
everi
day
complet
survey
endpoint
assess
treatment
group
placebo
vs
armsi
multipl
daili
observ
individu
studi
nomin
repeat
measur
per
subject
differ
subject
ordinari
logist
regress
model
inappropri
observ
within
subject
daytoday
would
expect
correl
therefor
gener
estim
equat
use
fit
regress
model
medic
visit
indic
whether
subject
went
emerg
depart
urgent
care
center
doctor
offic
due
uri
symptom
day
absente
indic
whether
subject
miss
school
work
would
miss
school
work
schedul
day
analyz
way
individu
symptom
analys
effect
vaccin
statu
outcom
assess
fit
multivari
logist
regress
model
treatment
arm
vaccin
statu
explanatori
variabl
total
individu
enrol
randomli
assign
two
treatment
arm
five
begin
studi
one
subject
placebo
group
return
followup
visit
exclud
analys
thu
analysi
result
perform
particip
placebo
group
armsi
group
see
fig
addit
file
consort
checklist
tabl
summar
demograph
studi
particip
age
studi
particip
rang
year
group
mean
age
year
placebo
group
year
activ
group
signific
differ
observ
two
group
p
gender
distribut
also
similar
two
studi
group
male
femal
placebo
group
respect
male
femal
activ
group
respect
studi
durat
number
day
enrol
rd
followup
visit
similar
placebo
group
armsi
group
total
survey
complet
studi
placebo
group
activ
group
moreov
percent
survey
complet
number
survey
complet
divid
studi
durat
similar
group
placebo
activ
group
respect
among
enrol
individu
six
particip
present
clinic
clinic
confirm
collect
oral
nasal
swab
relat
develop
uri
symptom
confirm
uri
episod
particip
present
confirm
uri
episod
four
belong
placebo
two
belong
activ
group
ci
p
indic
rel
reduct
latter
moreov
six
addit
subject
report
urirel
symptom
posttreat
visit
within
week
studi
complet
among
individu
four
placebo
group
two
activ
group
analys
diari
entri
show
one
addit
subject
activ
group
four
addit
subject
placebo
group
record
symptombas
uri
analys
show
cumul
frequenc
uri
tend
lower
individu
use
armsi
use
placebo
analys
symptom
report
studi
particip
daili
diari
show
total
occurr
uri
observ
individu
among
occur
placebo
group
individu
occur
activ
group
nine
individu
frequenc
uri
tend
higher
individu
placebo
group
activ
group
vs
respect
ci
indic
lower
rel
frequenc
uri
activ
group
analysi
data
base
daili
survey
event
symptom
also
reveal
similar
pattern
rel
reduct
frequenc
uri
activ
group
although
differ
signific
ci
analysi
sever
uri
show
fever
report
placebo
group
frequenc
cough
sore
throat
significantli
reduc
activ
group
tabl
p
moreov
sever
cough
sore
throat
also
significantli
reduc
activ
group
compar
placebo
group
frequenc
stuffi
nose
significantli
increas
activ
group
p
tabl
chisquar
analysi
symptom
individu
uri
show
rel
risk
cough
placebo
group
peopl
activ
group
rel
risk
sore
throat
peopl
activ
group
tabl
p
furthermor
multivari
logist
regress
analysi
indic
cough
symptom
associ
significantli
uri
less
cough
activ
group
placebo
vs
activ
p
ci
assess
durat
symptom
individu
report
urisrel
symptom
least
two
consecut
day
fever
report
placebo
group
durat
day
median
durat
cough
sore
throat
runni
nose
day
placebo
group
median
durat
symptom
day
respect
armsi
group
median
durat
stuffi
nose
malais
day
studi
group
maximum
durat
nonfev
symptom
day
placebo
group
durat
lower
day
activ
group
p
cough
comparison
safeti
toler
accept
adher
use
armsi
safeti
toler
accept
adher
evalu
oral
exam
solicit
unsolicit
advers
event
ae
endofstudi
accept
survey
selfreport
use
spray
part
studi
protocol
oral
exam
conduct
studi
particip
among
enrol
particip
abnorm
oral
exam
report
four
individu
three
belong
placebo
group
cheek
bite
two
labial
mucos
injuri
one
particip
one
activ
group
enlarg
tonsil
enrol
note
subsequ
visit
end
studi
none
oral
event
consid
relat
studi
drug
total
nine
advers
event
ae
report
studi
durat
five
occur
placebo
group
headach
two
anxieti
labial
mucos
injuri
muscl
strain
one
four
occur
activ
group
headach
two
anxieti
extrem
rash
one
none
ae
consid
relat
studi
medic
particip
ask
complet
exit
questionnair
question
relat
accept
activ
product
end
studi
found
respond
strongli
like
like
tast
activ
product
neutral
moreov
respond
favor
opinion
smell
strongli
like
like
neutral
product
addit
particip
state
would
recommend
product
other
major
express
willing
continu
use
product
studi
end
result
demonstr
armsi
high
accept
among
studi
particip
analysi
show
singlestream
spray
bottl
use
indic
day
placebo
activ
group
result
indic
studi
particip
exhibit
high
degre
complianc
appli
studi
drug
time
day
total
survey
complet
studi
placebo
activ
group
medic
care
question
left
blank
survey
thu
data
avail
survey
placebo
activ
group
among
individu
uri
two
medic
visit
placebo
arm
nine
absente
five
placebo
group
four
activ
group
result
show
medic
visit
occur
placebo
group
absente
differ
two
arm
pcr
analysi
perform
oral
nasal
swab
collect
individu
uri
show
presenc
influenza
b
coronaviru
rhinoviru
three
particip
detect
februari
march
april
respect
three
infect
particip
belong
placebo
arm
among
enrol
individu
report
receiv
influenza
vaccin
previous
belong
placebo
group
belong
activ
group
multivari
logist
regress
analysi
reveal
vaccin
statu
signific
effect
uri
p
result
show
vaccin
statu
influenc
uri
two
arm
current
studi
evalu
safeti
effect
armsi
novel
intraor
formul
prevent
uri
random
doubleblind
placebocontrol
proofofconcept
clinic
trial
healthi
adult
data
show
product
safe
well
toler
reduc
symptom
associ
influenza
use
armsi
associ
trend
reduc
frequenc
uri
studi
demonstr
armsi
safe
drugrel
advers
effect
expect
base
known
safeti
profil
activ
ingredi
long
histori
use
human
novel
patent
armsi
formul
contain
cetylpyridinium
chlorid
cpc
antimicrobi
xanthan
gum
glycerin
barrier
form
agent
ingredi
use
sinc
compon
variou
drug
product
includ
oral
spray
tablet
lozeng
capsul
concentr
similar
present
armsi
two
random
doubleblind
clinic
trial
report
efficaci
oral
administ
agent
prevent
uri
oneil
et
al
compar
efficaci
commerci
avail
echinacea
capsul
prevent
uri
symptom
compar
placebo
period
week
winter
month
report
echinacea
capsul
significantli
alter
frequenc
uri
symptom
bennett
et
al
determin
efficaci
low
dose
interferon
alpha
lozeng
prevent
uri
healthi
adult
n
age
year
base
weekli
health
data
questionnair
investig
report
lowdos
oral
prophylaxi
affect
incid
uri
reduc
sever
durat
symptom
studi
show
oral
topic
administr
activ
agent
associ
trend
frequenc
reduct
significantli
reduc
sever
durat
cough
sore
throat
associ
uri
interestingli
sever
runni
nose
increas
significantli
activ
group
frequenc
sever
stuffi
nose
could
link
fact
product
appli
oral
intranas
regard
lakdawala
et
al
identifi
soft
palat
oropharynx
import
site
isol
transmiss
viru
initi
site
infect
thu
drug
like
armsi
target
oropharynx
could
repres
novel
approach
prevent
viral
respiratori
infect
armsi
possess
dual
mechan
action
target
host
form
barrier
prevent
contact
viru
host
mucosa
b
exert
direct
virucid
activ
disrupt
outer
viral
membran
sinc
cpc
antivir
compon
armsi
target
hostderiv
lipid
membran
physicochem
interact
target
viral
protein
activ
armsi
unlik
affect
mutat
viral
genom
thu
armsi
addit
advantag
low
potenti
develop
resist
limit
current
studi
includ
underpow
low
incid
uri
cohort
may
due
season
natur
uri
well
particip
record
uri
diari
present
clinic
potenti
confound
variabl
includ
ethnic
occup
statu
comorbid
chronic
respiratori
diseas
futur
plan
investig
intend
power
clinic
trial
base
low
incid
uri
well
conduct
studi
multipl
site
multipl
season
armsi
safe
welltoler
reduc
influenza
symptom
product
potenti
prevent
viral
upper
respiratori
tract
infect
clinic
develop
novel
product
warrant
